Overview
Title
An Act To extend the Gabriella Miller Kids First Pediatric Research Program at the National Institutes of Health, and for other purposes.
ELI5 AI
This bill is like making sure a favorite science project about helping sick kids can keep going for a few more years, with plans to check how well it's working, but it doesn't explain exactly how they will use the money or what they hope to achieve.
Summary AI
H. R. 3391, titled the "Gabriella Miller Kids First Research Act 2.0," aims to extend the Pediatric Research Program at the National Institutes of Health (NIH) until 2028. The bill amends the Public Health Service Act to ensure continued funding and coordination of pediatric research by redirecting funds to the Division of Program Coordination, Planning, and Strategic Initiatives. It emphasizes avoiding duplication of research efforts and requires a progress report on investments in pediatric research to be submitted to Congress within five years of enactment. The bill was passed by the House on March 5, 2024.
Published
Keywords AI
Sources
Bill Statistics
Size
Language
Complexity
AnalysisAI
General Summary of the Bill
The bill titled "Gabriella Miller Kids First Research Act 2.0" seeks to extend and modify the existing Gabriella Miller Kids First Pediatric Research Program at the National Institutes of Health (NIH). Specifically, the bill aims to continue funding and support for the Pediatric Research Initiative from 2024 through 2028. It redefines the allocation and coordination efforts for pediatric research, focusing on certain administrative changes within the Public Health Service Act.
Summary of Significant Issues
Several significant issues arise from the legislation. A key concern is the lack of detailed allocation strategies for the funds earmarked for pediatric research. This absence of specifics could lead to potential oversight problems and a lack of accountability in distributing resources. Additionally, the bill replaces the reference to the "Common Fund" with the "Division of Program Coordination, Planning, and Strategic Initiatives" without fully explaining the implications of this shift, potentially creating ambiguity about its impact on previously funded projects.
There is also an issue with the transition of the funding period without explicitly stated goals or expected results. This lack of clarity may hinder stakeholders from understanding the intended outcomes of the extended funding and its impact on pediatric research.
The bill's approach to avoiding duplication in research efforts lacks a clear mechanism or criteria, which might result in redundant research activities and inefficient use of resources. Moreover, the legislation does not provide specific criteria for evaluating advancements in pediatric research, leading to potential inconsistencies in reporting progress.
Impact on the Public Broadly
This bill broadly aims to enhance pediatric research, which could have significant long-term benefits for pediatric healthcare. By focusing more resources on this area, the potential for breakthroughs in cancer treatment and other pediatric diseases could improve healthcare outcomes for children. However, without explicit directives on how these resources should be allocated and monitored, the effectiveness of the bill could be diminished.
Impact on Specific Stakeholders
Various stakeholders could be affected by the bill in different ways. For researchers and institutions involved in pediatric studies, the bill offers extended funding opportunities but may also introduce uncertainty due to ambiguous guidelines on fund allocation and project prioritization. This uncertainty could affect planning and execution of research projects.
For policymakers and oversight bodies, ensuring accountability and determining the success of the funding period extension could be challenging without clear goals or criteria. Moreover, families and patients awaiting medical advances might experience frustration or disappointment if the anticipated research impacts are delayed or unattained due to inefficient fund utilization.
In summary, while the Gabriella Miller Kids First Research Act 2.0 is poised to advance pediatric research by securing additional resources, its effectiveness may be hindered by the lack of specificity in fund management, priority setting, and progress reporting. Addressing these issues could enhance the legislation's impact and benefit stakeholders significantly.
Issues
The section on Funding for the Pediatric Research Initiative (Section 2) does not provide specific details on how funds will be allocated, which could lead to potential oversight issues or lack of accountability, as stakeholders will not have a clear understanding of how resources are being distributed.
The amendment's transition from the 'Common Fund' to the 'Division of Program Coordination, Planning, and Strategic Initiatives' in Section 2 is not clearly explained, causing potential ambiguity in terms of impact on previously funded initiatives. This change may affect how programs are prioritized and funded, making it a significant issue for stakeholders.
The modification in Section 2 by extending the funding period from '2014 through 2023' to '2024 through 2028' without declaring expected outcomes or goals leaves ambiguity regarding the effectiveness or impact of these extensions on pediatric research.
Section 3's lack of a clear mechanism or criteria for avoiding duplication of existing research activities could lead to inefficient use of resources and redundant research efforts, hampering overall pediatric research progress.
The absence of a planning or evaluation method in Section 3 for assessing the effectiveness of coordination and prioritization efforts might result in inefficiencies or lack of accountability, potentially undermining the intended goals of improving pediatric research coordination.
Section 4 does not specify the criteria or metrics for evaluating 'advancements made in pediatric research,' which might result in subjective or inconsistent reporting. This could lead to challenges in evaluating the true progress and impact of funded research initiatives.
There is no clear definition provided for what constitutes 'pediatric research' in Section 4, potentially leading to misunderstandings about eligible projects and initiatives, which could complicate the evaluation and funding process.
Sections
Sections are presented as they are annotated in the original legislative text. Any missing headers, numbers, or non-consecutive order is due to the original text.
1. Short title Read Opens in new tab
Summary AI
Section 1 provides the short title of the bill, which is officially named the "Gabriella Miller Kids First Research Act 2.0."
2. Funding for the Pediatric Research Initiative Read Opens in new tab
Summary AI
The section amends the Public Health Service Act to reallocate funding to the Division of Program Coordination, Planning, and Strategic Initiatives for pediatric research from 2024 to 2028, updating several legislative references and removing outdated terms related to the Common Fund.
3. Coordination of NIH funding for pediatric research Read Opens in new tab
Summary AI
The section highlights that Congress believes the Director of the National Institutes of Health should keep overseeing and coordinating research on pediatric diseases like cancer. It also amends a part of the Public Health Service Act to ensure that this pediatric research focuses on areas that don't duplicate existing National Institutes of Health research.
4. Report on progress and investments in pediatric research Read Opens in new tab
Summary AI
The Secretary of Health and Human Services is required to submit a report to Congress within five years of the law's enactment. This report should include details on pediatric research projects funded under a specific section of the Public Health Service Act and a summary of advancements made in pediatric research with those funds.